International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 5 , Pages 1323-1331 , 1 April 2007

A Phase II Multi-institutional Trial of Chemoradiation Using Weekly Docetaxel and Erythropoietin for High-Risk Postoperative Head and Neck Cancer Patients

The results of this study were previously presented at the 2004 American Society of Clinical Oncology meeting.

  • Christopher D. Willey, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Barbara A. Murphy, M.D.

      Affiliations

    • Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • James L. Netterville, M.D.

      Affiliations

    • Department of Otolaryngology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Brian B. Burkey, M.D.

      Affiliations

    • Department of Otolaryngology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Yu Shyr, Ph.D.

      Affiliations

    • Department of Head and Neck Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Bashar Shakhtour, B.S.

      Affiliations

    • Department of Head and Neck Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • Bonnie Kish, R.N.

      Affiliations

    • Department of Biostatistics, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • ,
  • David Raben, M.D.

      Affiliations

    • Department of Clinical Trials Office, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Changhu Chen, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • John I. Song, M.D.

      Affiliations

    • Department of Otolaryngology, University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • Madeleine A. Kane, M.D., Ph.D.

      Affiliations

    • Department of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado
    • ,
  • Anthony J. Cmelak, M.D.

      Affiliations

    • Department of Radiation Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
    • Corresponding Author InformationReprint requests to: Anthony J. Cmelak, M.D., Radiation Oncology, Vanderbilt-Ingram Cancer Center, B-902, The Vanderbilt Clinic, Nashville, TN 37232-5671. Tel: (615) 343-9462; Fax: (615) 343-0161

Received 11 September 2006 ,Revised 14 November 2006 ,Accepted 17 November 2006.

References 

  1. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952
  2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  3. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561–1565
  4. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994;12:1458–1467
  5. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol. 1993;11:950–958
  6. Choy H, Rodriguez FF, Koester S, et al. Investigation of taxol as a potential radiation sensitizer. Cancer. 1993;71:3774–3778
  7. Tishler RB, Schiff PB, Geard CR, et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992;22:613–617
  8. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842–1850
  9. Chaffey JT, Hellman S. Differing responses to radiation of murine bone marrow stem cells in relation to the cell cycle. Cancer Res. 1971;31:1613–1615
  10. Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20:3806–3813
  11. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56:816–825
  12. Baker SD, Zhao M, Lee CK, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004;10:1976–1983
  13. Schoffski P, Weihkopf T, Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: Docetaxel. Anticancer Res. 1998;18:4751–4756
  14. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672–1678
  15. Schoffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (Results of a phase II study of the EORTC Early Clinical Studies Group). Ann Oncol. 1999;10:119–122
  16. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck—The Dana Farber Cancer Institute experience. Cancer. 2003;97:412–418
  17. Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. British J Cancer. 2003;88:11–17
  18. Nabell L, Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol. 2003;30:89–93
  19. Vermorken JB, Remenar E, van Herpen C. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol. 2004;22(Suppl):490s–490s
  20. Posner MR. Paradigm shift in the treatment of head and neck cancer: The role of neoadjuvant chemotherapy. Oncologist. 2005;10(Suppl 3):11–19
  21. Kodaira T, Fuwa N, Furutani K, et al. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol. 2005;35:173–176
  22. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004;15:1358–1365
  23. Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16:90–96
  24. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer (The DISTAL 01 study). Br J Cancer. 2004;91:1996–2004
  25. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer-patients during radiation-therapy. Int J Radiat Oncol Biol Physics. 1993;27:1147–1152
  26. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113–117
  27. Prosnitz RG, Yao B, Farrell CL, et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Physics. 2005;61:1087–1095
  28. Blohmer JU, Wurschmidt F, Petry U. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high risk cervical cancer. Proc Am Soc Clin Oncol. 2003;22:447
  29. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003;98:1072–1079
  30. Rades D, Schild SE, Yekebas EF, et al. Epoetin-alpha during radiotherapy for stage III esophageal carcinoma. Cancer. 2005;103:2274–2279
  31. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  32. Dobrowsky W, Naude J, Widder J, et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys. 1998;42:803–806
  33. Dobrowsky W, Naude J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol. 2000;57:119–124
  34. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol. 1998;16:1318–1324
  35. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  36. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma (Results of the 98–02 GORTEC Phase II trial). Int J Radiat Oncol Biol Phys. 2004;58:161–166
  37. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region (A meta-analysis of prospective and randomized trials). J Clin Oncol. 1996;14:838–847
  38. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83–91
  39. Bourhis J, Pignon JP. Meta-analyses in head and neck squamous cell carcinoma (What is the role of chemotherapy?). Hematol Oncol Clin North Am. 1999;13:769–775vii
  40. Pignon JP, Bourhis J, Domenge C, et al. MACH-NC Collaborative Group Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data (Meta-Analysis of Chemotherapy on Head and Neck Cancer). Lancet. 2000;355:949–955
  41. Pignon JP, Baujat B, Bourhis J. [Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?]. Cancer Radiother. 2005;9:31–36[In French]
  42. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?. Oncologist. 2005;10:215–224
  43. Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol. 1996;14:600–609
  44. Brockstein B, Haraf DJ, Stenson K, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998;16:735–744
  45. Vokes EE, Mauer AM, Hoffman PC, et al. Combined modality therapy in non–small cell lung and esophageal cancer: A phase I dose-escalation study of docetaxel with concurrent radiotherapy. Semin Oncol. 1998;25:28–32
  46. Formenti SC, Symmans WF, Volm M, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol. 1999;9:34–42
  47. Choy H, Safran H, Akerley W, et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non–small cell lung cancer. Clin Cancer Res. 1998;4:1931–1936
  48. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non–small cell lung cancer (A phase I/II dose escalation trial). Eur J Cancer. 1998;34:838–844
  49. Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998;16:159–164
  50. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A Phase I/II trial. J Clin Oncol. 1998;16:1331–1339
  51. Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999;17:3503–3511
  52. Posner MR, Glisson B, Frenette G, et al. Multicenter Phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096–1104
  53. Colevas AD, Norris CM, Tishler RB, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol. 2002;25:153–159
  54. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002;95:322–330
  55. Dunphy FR, Dunleavy TL, Harrison BR, et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma (Analysis of 62 patients treated between 1994 and 1999). Cancer. 2001;91:940–948
  56. Haddad R, Tishler RB, Norris CM, et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003;8:35–44
  57. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636–8645
  58. Allal AS, Zwahlen D, Becker M, et al. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. Cancer J. 2006;12:63–68
  59. Tishler RB, Norris CM, Colevas AD. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer. 2002;95:1472–1481
  60. Fujii M, Tsukuda M, Satake B, et al. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2004;9:107–112
  61. Kovacs AF. Maximized combined modality treatment of an unselected population of oral and oropharyngeal cancer patients (Final results of a pilot study compared with a treatment-dependent prognosis index). J Craniomaxillofac Surg. 2006;34:74–84
  62. Kovacs AF, Schiemann M, Turowski B. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel—three year results of a pilot study. J Craniomaxillofac Surg. 2002;30:112–120
  63. Suzuki M, Nishimura Y, Nakamatsu K, et al. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol. 2003;33:297–301
  64. Kovacs AF, Mose S, Bottcher HD, et al. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol. 2005;181:26–34
  65. Tishler RB, Posner MR, Norris CM, et al. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006;65:1036–1044
  66. Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol. 2000;27:13–24
  67. Janinis J, Papadakou M, Panagos G, et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol. 2001;24:227–231
  68. Hitt R, Amador ML, Quintela-Fandino M, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006;106:106–111
  69. Mote PA, Davey MW, Davey RA, et al. Paclitaxel sensitizes multidrug resistant cells to radiation. Anticancer Drugs. 1996;7:182–188
  70. Riese NE, Buswell L, Noll L, et al. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85–27 phase III head and neck trial. Int J Radiat Oncol Biol Phys. 1997;39:855–858
  71. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85–27. Int J Radiat Oncol Biol Physics. 1998;42:1069–1075
  72. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local-control and survival of T1-T2 squamous-cell carcinomas of the glottic larynx. J Clinical Oncol. 1995;13:2077–2083
  73. Overgaard J, Hansen HS, Jorgensen K, et al. Primary radiotherapy of larynx and pharynx carcinoma—an analysis of some factors influencing local-control and survival. Int J Radiat Oncol Biol Physics. 1986;12:515–521
  74. Cortesi E, Gascon P, Henry D, et al. Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life. Oncology. 2005;68(Suppl 1):22–32
  75. Hudis CA, Van Belle S, Chang J, et al. rHuEPO and treatment outcomes: The clinical experience. Oncologist. 2004;9(Suppl 5):55–69
  76. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  77. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459–460
  78. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  79. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63:25–36
  80. Biete Sola A, Calvo Manuel FA, Clavo Varas B, et al. Erythropoietin in cancer treatment: considerations about Henke’s article. Clin Transl Oncol. 2005;7:332–335
  81. Kaanders JH, van der Kogel AJ. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 2004;363:78–79author reply 81–72
  82. Leyland-Jones B, Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet. 2004;363:80;author reply 81–82
  83. Machtay M, Pajak T, Suntharalingam M, et al. Definitive radiotherapy +/− erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99–03. Int J Radiat Oncol Biol Physics. 2004;60:S132–S132

 This research was supported by Sanofi Aventis.Conflict of interest: none.

PII: S0360-3016(06)03504-8

doi: 10.1016/j.ijrobp.2006.11.033

International Journal of Radiation Oncology * Biology * Physics
Volume 67, Issue 5 , Pages 1323-1331 , 1 April 2007

Article Tools

* Image Usage & Resolution